An Open Letter to Health Canada

Abstract

Get full access to this article

View all access options for this article.

References

Targan

Feagan

Vermeire

. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2016;111(11):1599-1607.

Food and Drug Administration. FDA briefing document: dermatologic and ophthalmic drugs advisory committee meeting July 10, 2016. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM511357.pdf. Accessed January 12, 2017.

Lebwohl

Strober

Menter

. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318-1328.

Drapeau

McIntosh

, American Association of Suicidology. U.S.A. suicide: Official final data. http://www.suicidology.org/Portals/14/docs/Resources/FactSheets/2015/2015datapgsv1.pdf?ver=2017-01-02-220151-870. Published December 23, 2016. Accessed February 20, 2017.

Tyring

Gottlieb

Papp

. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367(9504):29-35.

Papp

Reich

Paul

. Improvements in depression and anxiety with brodalumab therapy in AMAGINE-1, a phase 3 study for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;74(5)(suppl 1):AB254.

Menter

Reich

Warren

. Impact of ixekzumab treatment on depressive symptoms: an integrated analysis of three phase 3 clinical studies in patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2016;74(5)(suppl 1):AB253.

http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf. Accessed February 20, 2017.